Prestige Consumer Healthcare (NYSE:PBH) VP Sells $65,930.00 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. The trade was a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jeffrey Zerillo also recently made the following trade(s):

• On Monday, December 1st, Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $60.00, for a total value of $16,860.00.
• On Friday, November 28th, Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00.

Prestige Consumer Healthcare Stock Down 0.2%

NYSE:PBH traded down $0.15 during trading hours on Friday, reaching $66.81. The company had a trading volume of 289,360 shares, compared to its average volume of 383,485. Prestige Consumer Healthcare Inc. has a twelve month low of $57.25 and a twelve month high of $90.04. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of 17.67, a P/E/G ratio of 2.08 and a beta of 0.43. The business’s 50-day simple moving average is $63.69 and its two-hundred day simple moving average is $63.78.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same quarter in the prior year, the business earned $1.22 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC increased its holdings in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after buying an additional 70,376 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth $1,890,000. AXQ Capital LP purchased a new position in Prestige Consumer Healthcare in the second quarter worth $694,000. Tributary Capital Management LLC increased its stake in Prestige Consumer Healthcare by 157.3% in the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after acquiring an additional 231,969 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Prestige Consumer Healthcare by 51.8% in the second quarter. Franklin Resources Inc. now owns 33,476 shares of the company’s stock valued at $2,673,000 after acquiring an additional 11,429 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

PBH has been the topic of several recent research reports. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Oppenheimer dropped their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Finally, Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).